Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo

Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01006421

Acronym

Enrollment

160

Registered

2009-11-02

Start date

2009-01-31

Completion date

2011-01-31

Last updated

2009-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Keywords

phototherapy, Gingko biloba, repigmentation

Brief summary

Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available. Phototherapy is among the successful treatments but gives modest results. Some reports documented the usefulness of Ginkgo Biloba (GB) when used alone in Vitiligo treatment.

Detailed description

Adding GB to phototherapy, especially the most commonly used one; Narrow-Band UVB (NBUVB) might give better results than using either one alone. This might improve repigmentation as well as patients' quality-of-life. (QOL). This will be a prospective double-blind randomized controlled clinical trial. One-hundred-sixty Vitiligo patients will be randomly divided into 2 groups( 80 patients per group). One group will receive oral GB (2 tablets of 60 mgs twice daily) with NBUVB twice weekly. The other group will receive placebo tablets( identical in size, shape and color) to GB twice daily with NBUVB twice weekly. Both groups will be treated for 6 months. Standard protocol of phototherapy will be used for both groups. Our aim here is to see whether adding GB to NBUVB will lead to better repigmentation than placebo or not.

Interventions

DIETARY_SUPPLEMENTGINGKO BILOBA

MEMOREX 60 MG BID

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Any Vitiligo patient (age 12 years and above) with non-segmental Vitiligo. * Body surface area (BSA) involvement ≥ 3%.

Exclusion criteria

* Unable to consent * Any topical, systemic or phototherapy for Vitiligo in the previous 2 months. * Pregnancy, breast feeding. * Liver or kidney disease. * Epilepsy * Bleeding disorder or anticoagulant treatment

Design outcomes

Primary

Measure	Time frame
Repigmentation (more than 50% from baseline) as the primary outcome	3,6 and 9 months

Secondary

Measure	Time frame
Quality-of-life - as secondary outcome .	3,6 and 9 months

Countries

Saudi Arabia

Contacts

Primary ContactKHALID M ALGHAMDI, MD

kmgderm@yahoo.com4690815

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026